SAN FRANCISCO — It’s hard to remember amid all the cocktail parties, panel sessions, networking meetings, and general glad-handing, but there’s an actual health care investor conference at the heart of the biotech industry’s gathering here each January.

Thousands of people flock to the J.P. Morgan Healthcare Conference but never actually step inside the conference’s home base at the Westin St. Francis Hotel on the western side of Union Square. They’re off doing other biotechy things. But about 9,000 people — executives from 450 biotech and drug companies plus investors and ne’er-do-wells like, ahem, journalists — do actually attend the conference.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • For Gilead, I hope someone would ask John Milligan for the status of Hrvoni and Epclusa approval and launch in china, when would Ovladi get on the country and regional lists, and what are the projections for revenue for all three drugs in 2018. Finally what about GLPG acquisitions in 2018.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy